Q9UI95 (MD2L2_HUMAN) Homo sapiens (Human)
Mitotic spindle assembly checkpoint protein MAD2B UniProtKBInterProSTRINGInteractive Modelling
211 aa; Sequence (Fasta) ;
16 identical sequences
It is possible new templates exist for this target since these models were created.
Available Structures
24 Experimental Structures
| Description | PDB ID | Oligo-state | Range | Ligands | ||
|---|---|---|---|---|---|---|
| Crystal structure of Rev7-K44A/R124A/A135D in complex with Rev3-RBM2 (residues 1988-2014) |
Heteromer O60673; | |||||
| Assess | ||||||
| Crystal structure of Rev7-R124A/Rev3-RBM2 (residues 1988-2014) complex |
Heteromer O60673; | 2×SO4; 2×ACT; | ||||
| Assess | ||||||
| Rational drug design of phenazopyridine derivatives as novel inhibitors of Rev1-CT |
Heteromer O60673; Q9UBZ9; | 1×U8M; | ||||
| Assess | ||||||
| Crystal structure of MAD2L2/REV7 in complex with a CAMP fragment in a tetragonal crystal |
Heteromer Q96JM3; | |||||
| Assess | ||||||
| Structure of polymerase-interacting domain of human Rev1 in complex with translesional synthesis po… |
Heteromer O60673; Q9UBZ9; | |||||
| Assess | ||||||
| Crystal structure of human SHLD3-C-REV7-O-REV7-SHLD2 complex |
Heteromer Q6ZNX1; Q86V20; | |||||
| Assess | ||||||
| Structure of human SHLD2-SHLD3-REV7-TRIP13(E253Q) complex |
Heteromer Q15645; Q6ZNX1; Q86V20; | 5×AGS; | ||||
| Assess | ||||||
| Structure of REV7-R124A complexed with SHLD3(37-73) |
Heteromer Q6ZNX1; | |||||
| Assess | ||||||
| X-ray structure of human REV7 in complex with Shieldin3 (residues 41-74) |
Heteromer Q6ZNX1; | 3×SO4; | ||||
| Assess | ||||||
| Structure of REV7-R124A complexed with SHLD3(28-73) |
Heteromer Q6ZNX1; | |||||
| Assess | ||||||
| Crystal structure of human Rev3-Rev7-Rev1 complex |
Heteromer O60673; Q9UBZ9; | |||||
| Assess | ||||||
| Crystal structure of human Rev3-Rev7-Rev1-Polkappa complex |
Heteromer O60673; Q9UBT6; Q9UBZ9; | |||||
| Assess | ||||||
| Structure of human REV7 in complex with a human REV3 fragment in a monoclinic crystal |
Heteromer O60673; | |||||
| Assess | ||||||
| Structure of human REV7 in complex with a human REV3 fragment in a tetragonal crystal |
Heteromer O60673; | |||||
| Assess | ||||||
| Crystal structure of REV7(R124A) in complex with a Shieldin3 fragment |
Heteromer Q6ZNX1; | 1×SO4; | ||||
| Assess | ||||||
| Crystal structure of REV7(R124A/A135D) in complex with a Shieldin3 fragment |
Heteromer Q6ZNX1; | 1×SO4; | ||||
| Assess | ||||||
| Crystal structure of REV1-REV7-REV3 ternary complex |
Heteromer O60673; Q9UBZ9; | |||||
| Assess | ||||||
| Rational drug design of phenazopyridine derivatives as novel inhibitors of Rev1-CT |
Heteromer O60673; Q9UBZ9; | |||||
| Assess | ||||||
| Crystal structure of Rev7-WT/Rev3 as a monomer under high-salt conditions |
Heteromer O60673; | |||||
| Assess | ||||||
| Crystal structure of human REV7(R124A)-SHLD3(35-58) complex |
Heteromer Q6ZNX1; | |||||
| Assess | ||||||
| Crystal structure of human SHLD2-SHLD3-REV7 complex |
Heteromer Q6ZNX1; Q86V20; | |||||
| Assess | ||||||
| Crystal structure of MAD2L2/REV7 in complex with a CAMP fragment in a monoclinic crystal |
Heteromer Q96JM3; | |||||
| Assess | ||||||
| crystal structure of MBP-tagged REV7-IpaB complex | homo-4-mer | |||||
| Assess | ||||||
| crystal structure of human REV7-RAN complex | monomer | |||||
| Assess | ||||||
1 SWISS-MODEL model
| Template | Oligo-state | QMEANDisCo | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|
| 6m7b.1.B | monomer | 0.84 | 99.53 | |||
| Assess | ||||||